CN106620351A - 一种治疗和预防流感的中药组合物及其制备方法 - Google Patents
一种治疗和预防流感的中药组合物及其制备方法 Download PDFInfo
- Publication number
- CN106620351A CN106620351A CN201710030459.XA CN201710030459A CN106620351A CN 106620351 A CN106620351 A CN 106620351A CN 201710030459 A CN201710030459 A CN 201710030459A CN 106620351 A CN106620351 A CN 106620351A
- Authority
- CN
- China
- Prior art keywords
- parts
- filtrate
- chinese medicine
- hours
- treating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 25
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- 239000002994 raw material Substances 0.000 claims abstract description 16
- 206010022000 influenza Diseases 0.000 claims abstract description 11
- 240000003915 Lophatherum gracile Species 0.000 claims abstract description 9
- 244000068988 Glycine max Species 0.000 claims abstract description 8
- 235000010469 Glycine max Nutrition 0.000 claims abstract description 8
- 235000006753 Platycodon grandiflorum Nutrition 0.000 claims abstract description 8
- 244000269722 Thea sinensis Species 0.000 claims abstract description 8
- 235000009569 green tea Nutrition 0.000 claims abstract description 8
- 239000000706 filtrate Substances 0.000 claims description 34
- 239000007788 liquid Substances 0.000 claims description 29
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 24
- 239000000203 mixture Substances 0.000 claims description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 15
- 239000006228 supernatant Substances 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 9
- 244000111489 Gardenia augusta Species 0.000 claims description 8
- 235000018958 Gardenia augusta Nutrition 0.000 claims description 8
- 241000555712 Forsythia Species 0.000 claims description 7
- 240000003582 Platycodon grandiflorus Species 0.000 claims description 7
- 239000004383 Steviol glycoside Substances 0.000 claims description 7
- 239000001771 mentha piperita Substances 0.000 claims description 7
- 229930182488 steviol glycoside Natural products 0.000 claims description 7
- 235000019411 steviol glycoside Nutrition 0.000 claims description 7
- 150000008144 steviol glycosides Chemical class 0.000 claims description 7
- 235000019202 steviosides Nutrition 0.000 claims description 7
- 230000008569 process Effects 0.000 claims description 6
- 239000008213 purified water Substances 0.000 claims description 6
- 238000000605 extraction Methods 0.000 claims description 5
- 238000010298 pulverizing process Methods 0.000 claims description 5
- 238000012805 post-processing Methods 0.000 claims description 2
- 239000000498 cooling water Substances 0.000 claims 1
- 238000005538 encapsulation Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 16
- 229940079593 drug Drugs 0.000 abstract description 6
- 208000011580 syndromic disease Diseases 0.000 abstract description 4
- 239000000796 flavoring agent Substances 0.000 abstract description 2
- 235000019634 flavors Nutrition 0.000 abstract description 2
- 244000291564 Allium cepa Species 0.000 abstract 1
- 235000002732 Allium cepa var. cepa Nutrition 0.000 abstract 1
- 241000555682 Forsythia x intermedia Species 0.000 abstract 1
- 244000303040 Glycyrrhiza glabra Species 0.000 abstract 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 abstract 1
- 241000207840 Jasminum Species 0.000 abstract 1
- 235000010254 Jasminum officinale Nutrition 0.000 abstract 1
- 235000006679 Mentha X verticillata Nutrition 0.000 abstract 1
- 235000002899 Mentha suaveolens Nutrition 0.000 abstract 1
- 235000001636 Mentha x rotundifolia Nutrition 0.000 abstract 1
- 244000274050 Platycodon grandiflorum Species 0.000 abstract 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 abstract 1
- 235000011477 liquorice Nutrition 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 28
- 241001465754 Metazoa Species 0.000 description 16
- 238000012360 testing method Methods 0.000 description 14
- 241000699666 Mus <mouse, genus> Species 0.000 description 13
- 230000000242 pagocytic effect Effects 0.000 description 8
- 230000037396 body weight Effects 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 210000003743 erythrocyte Anatomy 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 230000003442 weekly effect Effects 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- 230000034994 death Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 241000287828 Gallus gallus Species 0.000 description 4
- 208000005374 Poisoning Diseases 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 230000037406 food intake Effects 0.000 description 4
- 235000012631 food intake Nutrition 0.000 description 4
- 231100000572 poisoning Toxicity 0.000 description 4
- 230000000607 poisoning effect Effects 0.000 description 4
- 102000001554 Hemoglobins Human genes 0.000 description 3
- 108010054147 Hemoglobins Proteins 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 230000002489 hematologic effect Effects 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 231100000460 acute oral toxicity Toxicity 0.000 description 2
- 231100000403 acute toxicity Toxicity 0.000 description 2
- 230000007059 acute toxicity Effects 0.000 description 2
- 210000003484 anatomy Anatomy 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000005784 autoimmunity Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 208000023504 respiratory system disease Diseases 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 238000012109 statistical procedure Methods 0.000 description 2
- 210000001550 testis Anatomy 0.000 description 2
- 206010004542 Bezoar Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 241000576429 Forsythia suspensa Species 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 1
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 101000981253 Mus musculus GPI-linked NAD(P)(+)-arginine ADP-ribosyltransferase 1 Proteins 0.000 description 1
- 241000233855 Orchidaceae Species 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000009798 acute exacerbation Effects 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000146 antalgic effect Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000003260 anti-sepsis Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 208000030303 breathing problems Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- -1 flavone compound Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 230000007674 genetic toxicity Effects 0.000 description 1
- 231100000025 genetic toxicology Toxicity 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 210000001630 jejunum Anatomy 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 210000003024 peritoneal macrophage Anatomy 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000004088 pulmonary circulation Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 150000008130 triterpenoid saponins Chemical class 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/346—Platycodon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/534—Mentha (mint)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
- A61K36/634—Forsythia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
- A61K36/744—Gardenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8962—Allium, e.g. garden onion, leek, garlic or chives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种治疗和预防流感的中药组合物及其制备方法,原材料有效成分的质量分数为：桔梗1‑2份，甘草2‑3份，绿茶2‑3份，栀子2‑3份，薄荷叶1‑2份，葱白3‑5份，淡豆豉1‑2份，淡竹叶2‑3份，连翘叶1‑2份。本品成本低廉，可长期服用，具有辛凉解表、疏风散热作用，可用于风温、风热初起，感冒、流行性感冒。
Description
技术领域
本发明涉及中药配方，尤其涉及一种治疗和预防流感的中药组合物及其制备方法。
背景技术
随着现代生活节奏的加快，空气中的颗粒灰尘漂浮物导致空气质量直线下降，频繁出现浓雾、霾等天气现象，而感染呼吸道疾病的患者也因此不断增加。在雾霾天气下，空气中大量污染物颗粒无法扩散，使得病毒和细菌更容易传播，PM2.5会进入呼吸道，导致气管黏膜杀灭病毒、细菌和抵抗它们进入肺部组织的功能下降，原本身体健康的人群可能会出现咳嗽症状，患有哮喘等呼吸疾病的人群则会发生肺部感染，出现气短、胸闷等不适甚至急性加重反应。
如申请号为20131052421211公开了一种治流感的中药组合物，也主要用中药材进行治理，但是其配方中加入了牛黄，其价格较高，且药性较猛，不适合人们长期服用。
目前市场上治疗因雾霾引起的上呼吸道感染多采用药物治疗，一般都是患者出现不适症状才使用，如抗感染抗生素、抗菌消炎的中成药等。现在人们急需一种结合中药调节免疫功能、改善肺部循环、镇痛抗炎、抑制病毒、增强自身免疫能力、且能长期服用的结合治疗和预防与一体的中药组合物。
发明内容
本发明的目的在于：本发明提供了一种可长期实用、效果较好的集治疗和预防流感双重效果的中药组合物及其制备方法。
本发明采用的技术方案如下：
一种治疗和预防流感的中药组合物,原材料的质量分数为：桔梗1-2份，甘草2-3份，绿茶2-3份，栀子2-3份，薄荷叶1-2份，葱白3-5份，淡豆豉1-2份，淡竹叶2-3份，连翘叶1-2份。
一种治疗和预防流感的中药组合物的制备方法，包括以下步骤：
步骤一、原料粉碎处理：将上述原料包括桔梗1-2份，甘草2-3份，绿茶2-3份，栀子2-3份，薄荷叶1-2份，葱白3-5份，淡豆豉1-2份，淡竹叶2-3份，连翘叶1-2份粉碎，过40目筛，备用；
步骤二、第一次加水煎煮：将上述原材料，加入12倍体积水量，煎熬2小时，过滤，得滤液一，滤渣二；
步骤三、第二次加水煎煮：将步骤二中的滤渣二加入8倍体积的水量，煎熬1小时，得 滤液二，滤渣二；
步骤四、滤液浓缩：将上述步骤所得滤液一和滤液二混合浓缩，缩至20℃下相对密度是1.20-1.25，得滤液三，备用；
步骤五、萃取：将滤液三中加入加乙醇使含醇量至体积含量75％，静置12小时，过滤取上清液；
步骤六、后处理：将步骤五中所得的上清液静置12小时，纯化水至40份，搅匀，封装。
可选地，所述步骤六取上清液，加矫味剂甜菊糖苷5份，静置12小时，过滤，煮沸30分钟，冷却后加纯化水至40份，搅匀，灌封。
综上所述，由于采用了上述技术方案，本发明的有益效果是：
1、主要利用原材料成分中的三萜皂苷以及黄酮类化合物，两者结合可以强化配方的增强人体免疫的功效；加入栀子、连翘、淡竹叶、薄荷等组成，效果更佳。而且本申请采用的配方对于人体无其他副作用，人体可以长期食用，增强自身免疫能力。
本申请中药配方产品成本低廉、服用简单、方便，易于被广大患者接受，具有社会价值和经济价值；产品中富含黄酮类、氨基酸、多糖、有机酸等有效成分，根据本品临床用药经验，表明本品具有辛凉解表、疏风散热作用，可用于风温、风热初起，现用于感冒、流行性感冒；本品制备工艺中不添加任何防腐剂，利用甘草等药自身的防腐功能，达到防腐作用。本配方为纯天然药食同源材料组合配方，一定程度上能改善呼吸道疾病患者症状，并对其所引发的其他疾病起预防作用。
2.加入矫味剂甜菊糖苷，可以改善该配方的味道，满足不同人群的饮用习惯。
具体实施方式
实施例1
原配方采用：桔梗50g，甘草100g，绿茶100g，栀子100g，薄荷叶50g，葱白150g，淡豆豉50g，淡竹叶50g，连翘叶100g。
步骤1，将上述原配方中的原料粉碎处理，过40目筛，备用；
步骤2，将步骤1中粉碎后的原材料，加入12倍体积水量，煎熬2小时，过滤，得滤液一，滤渣二；
步骤3，第二次加水煎煮：将步骤二中的滤渣二加入8倍体积的水量，煎熬1小时，得滤液二，滤渣二；
步骤4，滤液浓缩：将上述步骤所得滤液一和滤液二混合浓缩，缩至20℃下相对密度是1.20-1.25，得滤液三，备用；
步骤5、萃取：将滤液三中加入加乙醇使含醇量至体积含量75％，静置12小时，过滤取上清液；
步骤6，取上清液，加矫味剂甜菊糖苷10g，静置12小时，过滤，煮沸30分钟，冷却后加纯化水至2000ml，搅匀，灌封。
实施例2
原配方采用：桔梗37.5g，甘草75g，绿茶75g，栀子75g，薄荷叶37.5g，葱白112.5g，淡豆豉37.5g，淡竹叶37.5g，连翘叶75g。
步骤1，将上述原配方中的原料粉碎处理，过40目筛，备用；
步骤2，将步骤1中粉碎后的原材料，加入12倍体积水量，煎熬2小时，过滤，得滤液一，滤渣二；
步骤3，第二次加水煎煮：将步骤二中的滤渣二加入8倍体积的水量，煎熬1小时，得滤液二，滤渣二；
步骤4，滤液浓缩：将上述步骤所得滤液一和滤液二混合浓缩，缩至20℃下相对密度是1.20-1.25，得滤液三，备用；
步骤5、萃取：将滤液三中加入加乙醇使含醇量至体积含量75％，静置12小时，过滤取上清液；
步骤6，取上清液，加矫味剂甜菊糖苷7.5g，静置12小时，过滤，煮沸30分钟，冷却后加纯化水至1500ml，搅匀，灌封。
实施例3
原配方采用：桔梗25g，甘草50g，绿茶50g，栀子50g，薄荷叶25g，葱白100g，淡豆豉50g，淡竹叶50g，连翘叶25g，甜菊糖苷5g。
步骤1，将上述原配方中的原料粉碎处理，过40目筛，备用；
步骤2，将步骤1中粉碎后的原材料，加入12倍体积水量，煎熬2小时，过滤，得滤液一，滤渣二；
步骤3，第二次加水煎煮：将步骤二中的滤渣二加入8倍体积的水量，煎熬1小时，得滤液二，滤渣二；
步骤4，滤液浓缩：将上述步骤所得滤液一和滤液二混合浓缩，缩至20℃下相对密度是1.20-1.25，得滤液三，备用；
步骤5、萃取：将滤液三中加入加乙醇使含醇量至体积含量75％，静置12小时，过滤取上清液；
步骤6，取上清液，加矫味剂甜菊糖苷5g，静置12小时，过滤，煮沸30分钟，冷却后加纯化水至1000ml，搅匀，灌封。
为更好的说明本发明的有益效果，主要药效学研究如下：
(1)可明显增加大鼠的摄食量和体重，对脂肪重量和脂肪指数有增加趋势但无统计学意义。
(2)能增加小鼠的巨噬细胞吞噬功能，能明显增加小鼠免疫器官的重量和免疫器官脏器指数。
为进一步说明本申请的作用，下面是针对药效的具体研究实验以及相关数据(实验中所采用的口服液均采用上述方案制备而成)：
1.1急性毒性试验：给受试物后大、小鼠的一般表现和行为均未见异常，观察期内未见动物死亡(表1)，试验结束时，处死动物大体解剖肉眼未见异常。康晟口服液对大、小鼠急性经口MTD值均大于42g/㎏.BW(以生药计)，按急性毒性分级属无毒级。
表1康晟口服液对大、小鼠急性经口毒性试验结果
1.2.大鼠30天喂养试验
试验期间动物健康状况良好，体重持续增长，每组大鼠每天给予不同剂量的受试物后均未出现中毒症状，也未见动物死亡。
1.2.1康晟口服液对大鼠体重的影响
由表2可见，三个剂量组雌雄大鼠的初始体重、1-4周体重以及第30天的体重与对照组相比较，经统计学处理，无显著性差异(P>0.05)。
表2康晟口服液对大鼠体重的影响
1.2.2康晟口服液对大鼠每周进食量的影响
由表3可见，三个剂量组雌雄大鼠的每周进食量与对照组相比较，经统计学处理，均无显著性差异(P>0.05)。
表3康晟口服液对大鼠每周进食量的影响
1.2.3康晟口服液对大鼠食物利用率的影响
结果见表4，三个剂量组雌雄大鼠的每周食物利用率以及总食物利用率与对照组相比较，经统计学处理，无显著性差异(P>0.05)。
表4康晟口服液对大鼠食物利用率的影响
1.3样品：采用本方案制备。成人每日推荐量为20ml/60kg.BW(生药量：8.5g/60kg.BW)，
1.3.1试验动物：由成都生物制品研究所有限责任公司提供的昆明种小鼠160只，全雌，体重18－22g，生产许可证号为SCXK(川)2011－08SPF级；试验动物房为屏障系统，使用许可证号为SYXK(川)2011－043。温度20-25℃，相对湿度40—70％。饲料生产单位：四川省医学科学院四川省人民医院实验动物研究所，生产许可证号为SCXK(川)2010－001。
1.3.2剂量选择：受试物设1.5g/kg.BW、3g/kg.BW、6g/kg.BW三个剂量组(分别相当于人体推荐摄入量的10倍、20倍、40倍)
1.3.3NK细胞活性测定(乳酸脱氢酶LDH测定法)：颈椎脱臼处死动物，取出脾脏，撕碎，过200目筛网后，用Hank，s液洗3次，每次1000r/min离心10min，取细胞浆，灭菌水裂解红细胞，台酚兰染色计数(应在95％以上)，用完全1640培养液配成2×107个/ml细胞悬液。将各只小鼠的细胞悬液取300μl分置于96孔培养板中，每孔100μl，每孔加靶细胞(YAC-1细胞，4×105个/ml)100μl，同时做靶细胞自然释放孔(靶细胞100μl+培养液100μl)及最大释放孔(靶细胞100μl+2.5％Triton 100μl)各3孔，37℃5％CO2培养4小时，取出1500r/min离心5min。将各孔上清液100μl置于另一培养板中，每孔再加入100μl基质液，10分钟后加1mol/LHCL 30μl终止反应，在490nm处测定OD值，计算NK细胞活性率。
表5康晟口服液对小鼠NK细胞活性的影响
由表5可见，连续灌胃30天后，三个剂量组动物NK细胞活性与阴性对照组相比，经统计学处理，无显著性差异(P＞0.05)。
1.3.4小鼠腹腔巨噬细胞吞噬鸡红细胞试验(半体内法)：每只小鼠腹腔注射用NS洗涤3次后的20％鸡红细胞悬液1ml，30分钟后，颈椎脱臼处死，将其固定在鼠板上，正中剪开腹壁皮肤，经腹腔注入生理盐水2ml，转动鼠板1分钟，吸出腹腔洗液1ml，平均滴于2张载玻片上，置湿盒37℃30分钟，取出在生理盐水漂洗、晾干、固定，4％Giemsa PBS染色3分钟，蒸馏水漂洗凉干，镜检。计算吞噬百分率及吞噬指数。
康晟口服液对小鼠巨噬细胞吞噬鸡红细胞能力的影响
表6康晟口服液对小鼠巨噬细胞吞噬鸡红细胞能力的影响
由表6可见，连续灌胃30天后，三个剂量组动物的吞噬率和吞噬指数与阴性对照组相比，经统计学处理，无显著性差异(P＞0.05)。
该申请制备的口服液对小鼠单核—巨噬细胞吞噬功能试验结果阴性。
1.4
该申请制备的口服液对大鼠血液学的影响
由表7可见，三个剂量组雌雄大鼠的血液学指标检测结果与对照组相比较，经统计学处理，除雌鼠高剂量组的红细胞、血红蛋白显著高于对照组(p＜0.05)外，其余指标均无显著性差异(P>0.05)。以上所测值在本室正常值范围内。
表7康晟口服液对大鼠血液学指标的影响
注：*表示与对照组比较p＜0.05.
1.2.5康晟口服液对大鼠末期血生化的影响
由表7可见，三个剂量组雌雄大鼠的末期血生化指标检测结果与对照组相比较，经统计学处理，除雌鼠低剂量组谷草转氨酶显著高于对照组(p＜0.05)外，各项指标均无显著性差异(P>0.05)。
1.2.6康晟口服液对大鼠脏体比的影响
结果见表7，三个剂量组雌雄大鼠的肝体比、脾体比、肾体比以及雄鼠的睾丸体比值与 对照组相比较，经统计学处理，均无显著性差异(P>0.05)。
表7康晟口服液对大鼠脏体比的影响
1.2.7病理学检查
试验结束后处死动物，进行大体解剖，肉眼未见异常改变。组织病理学检查结果显示：对照组有2例肝组织汇管区局灶性轻度炎细胞浸润，其余受检组织均未见异常。以上所发现均为动物自发病变，未见受试物高剂量组引起动物中毒性损伤改变(见表8-14)。
表8康晟口服液对大鼠肝脏的组织学影响
表9康晟口服液对大鼠肾脏的组织学影响
表10康晟口服液对大鼠脾脏的组织学影响
表11对大鼠胃的组织学影响
表12康晟口服液对大鼠空肠的组织学影响
表13康晟口服液对大鼠睾丸的组织学影响
表14康晟口服液对大鼠卵巢的组织学影响
2.总结
2.1康晟口服液对大、小鼠急性经口毒性试验结果MTD值均大于15000mg/kg.BW,按急性毒性分级，属无毒级。
2.2三项遗传毒性试验(Ames试验、小鼠骨髓嗜多染红细胞微核试验以及小鼠精子畸形试验)结果未见口服液致突变作用。
2.3 30天喂养试验，可见动物生长发育正常，体重持续增长，体态活泼，大、小便未见异常改变。试验期间未见动物出现中毒症状及死亡。三个剂量组雌雄大鼠的每周体重、每周进食量、每周食物利用率及总食物利用率、脏体比值与对照组相比较，均无显著性差异(P＞0.05)；末期血液学指标除雌鼠高剂量组的红细胞、血红蛋白显著高于对照组(p＜0.05)，末期血生化指标除雌鼠低剂量组谷草转氨酶显著高于对照组(p＜0.05)外，其余指标均无显著性差异(P>0.05)；以上所测值均在本室正常值范围内。组织病理学检查结果，除动物自发病变外，未见受试物高剂量组引起动物中毒性损伤。
本方案对于动物无害，且提升血液学指标除雌鼠高剂量组的红细胞、血红蛋白含量，增强其免疫能力，从而达到治疗和预防的效果。
本说明书中公开的所有特征，除了互相排斥的特征和/或步骤以外，均可以以任何方式组合。
Claims (3)
1.一种治疗和预防流感的中药组合物,其特征在于，原材料的质量分数为：桔梗1-2份，甘草2-3份，绿茶2-3份，栀子2-3份，薄荷叶1-2份，葱白3-5份，淡豆豉1-2份，淡竹叶2-3份，连翘叶1-2份。
2.一种治疗和预防流感的中药组合物的制备方法，其特征在于，包括以下步骤：
步骤一、原料粉碎处理：将上述原料包括桔梗1-2份，甘草2-3份，绿茶2-3份，栀子2-3份，薄荷叶1-2份，葱白3-5份，淡豆豉1-2份，淡竹叶2-3份，连翘叶1-2份粉碎，过40目筛，备用；
步骤二、第一次加水煎煮：将上述原材料，加入12倍体积水量，煎熬2小时，过滤，得滤液一，滤渣二；
步骤三、第二次加水煎煮：将步骤二中的滤渣二加入8倍体积的水量，煎熬1小时，得滤液二，滤渣二；
步骤四、滤液浓缩：将上述步骤所得滤液一和滤液二混合浓缩，缩至20℃下相对密度是1.20-1.25，得滤液三，备用；
步骤五、萃取：将滤液三中加入加乙醇使含醇量至体积含量75％，静置12小时，过滤取上清液；
步骤六、后处理：将步骤五中所得的上清液静置12小时，纯化水至40份，搅匀，封装。
3.如权利要求2所述的一种治疗和预防流感的中药组合物的制备方法，其特征在于，所述步骤六取上清液，加矫味剂甜菊糖苷5份，静置12小时，过滤，煮沸30分钟，冷却后加纯化水至40份，搅匀，灌封。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710030459.XA CN106620351A (zh) | 2017-01-16 | 2017-01-16 | 一种治疗和预防流感的中药组合物及其制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710030459.XA CN106620351A (zh) | 2017-01-16 | 2017-01-16 | 一种治疗和预防流感的中药组合物及其制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106620351A true CN106620351A (zh) | 2017-05-10 |
Family
ID=58841801
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710030459.XA Pending CN106620351A (zh) | 2017-01-16 | 2017-01-16 | 一种治疗和预防流感的中药组合物及其制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106620351A (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107183243A (zh) * | 2017-05-18 | 2017-09-22 | 阜阳市四季旺食品有限公司 | 一种排毒瘦身竹叶清茶 |
-
2017
- 2017-01-16 CN CN201710030459.XA patent/CN106620351A/zh active Pending
Non-Patent Citations (2)
| Title |
|---|
| 张秀良: "《中老年食疗养生一本全》", 31 July 2016, 中国古籍出版社 * |
| 江山: "《老名方治常见病》", 31 March 2016, 中国古籍出版社 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107183243A (zh) * | 2017-05-18 | 2017-09-22 | 阜阳市四季旺食品有限公司 | 一种排毒瘦身竹叶清茶 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104664010B (zh) | 一种具有清咽保健功能的润喉糖组合物及其制备方法 | |
| CN105031197B (zh) | 一种具有润喉清咽功能的中药组合物及其制备方法与应用 | |
| CN101856418B (zh) | 防治肾炎的药物制剂及其制备方法 | |
| CN102462728A (zh) | 一种治疗和预防细菌性上呼吸道感染的药物组合物 | |
| EP3881685A1 (en) | Ceratonia siliqua fruit composition and preparation method therefor and use thereof | |
| CN103961614B (zh) | 用于治疗呼吸系统疾病的中药组合物及其制备方法和用途 | |
| CN107412713A (zh) | 治疗自体免疫性与免疫相关性疾病的中成药、医疗食品及制备方法 | |
| CN108523121A (zh) | 一种抗霾清肺的功能性食品及其制备方法 | |
| CN110772564A (zh) | 一种具有调节抑郁情绪作用的中药提取物组合物及其制备方法和中药制剂 | |
| CN106620351A (zh) | 一种治疗和预防流感的中药组合物及其制备方法 | |
| CN110151851A (zh) | 一种以金银花甘草药对为基础的复合物及其应用 | |
| CN111097002A (zh) | 一种清咽润喉中药组合物及其制备方法 | |
| CN106036894B (zh) | 一种改善癌症患者化疗症状的食品组合物及其制备方法 | |
| CN104664011B (zh) | 一种具有清咽保健功能的组合物及其制备方法 | |
| CN110090253B (zh) | 一种天然植物降脂组合物及其制备方法 | |
| KR102192586B1 (ko) | 아위버섯의 추출물 또는 분말을 유효성분으로 함유하는 지방간 질환 치료용 약학적 조성물 및 간기능 개선용 건강기능식품 | |
| CN103768153B (zh) | 用于治疗家禽气囊炎的中药组合物及其制备方法 | |
| CN106038975A (zh) | 一种具有止咳作用的中药组合物及其制备方法与用途 | |
| CN111557447A (zh) | 一种铁皮石斛多糖含片的制备及其在免疫增强作用上的应用 | |
| CN111480846A (zh) | 一种辅助降血脂、提高免疫力的保健品 | |
| CN106924448B (zh) | 治疗风热感冒的药物组合物及其制备方法 | |
| CN102973657A (zh) | 芩暴红止咳合剂及其制备方法 | |
| CN109260302A (zh) | 治疗气血不足的复方西洋参蜂王浆口服液及其制备方法 | |
| CN113101331B (zh) | 一种百里香药茶及其制备方法和应用 | |
| CN112641871B (zh) | 一种用于治疗痰热蕴肺的药物组合 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170510 |